Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : NIH begins clinical trial testing COVID-19 vaccine in pregnant women

06/23/2021 | 03:12pm EDT

June 23 (Reuters) - The U.S. National Institutes of Health (NIH) said on Wednesday it had begun a study to evaluate the immune responses generated by COVID-19 vaccines in pregnant or postpartum women.

Pregnant women are at higher risk of complications including premature birth, high blood pressure with organ failure risk, need for intensive care and possible death, according to the NIH.

A research study conducted in February in Israel showed that antibodies were detected in all 20 women administered with both the doses of the Pfizer/BioNTech vaccine during their third trimester of pregnancy and also in their newborns.

Pfizer and BioNTech in February started a separate trial, with 4,000 international volunteers, evaluating safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.

The NIH study, MOMI-VAX, will measure the development and durability of antibodies against the coronavirus in women vaccinated during pregnancy or the first two postpartum months.

The researchers will assess vaccine safety and also evaluate whether vaccinated pregnant women pass along protection to their babies via the placenta or breast milk.

Many pregnant women in the United States have already received the COVID-19 vaccine available under emergency use authorization.

"The results of this study will fill gaps in our knowledge and help inform policy recommendations and personal decision-making on COVID-19 vaccination during pregnancy," National Institute of Allergy and Infectious Diseases Director (NIAID) Dr Anthony Fauci said. NIAID is financing the study.

The trial will enroll up to 750 pregnant and 250 postpartum women within two months of delivery, who have already received or will receive a COVID-19 vaccine authorized by the U.S. Food and Drug Administration (FDA).

The FDA has authorized vaccines from Moderna, Pfizer-BioNTech and Johnson & Johnson for emergency use. (Reporting by Dania Nadeem in Bengaluru)


ę Reuters 2021
All news about MODERNA, INC.
05:13pHealth Care Down On Cyclical Bias -- Health Care Roundup
DJ
04:17pMODERNA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
04:10pNOVAVAX : again delays seeking U.S. approval for COVID-19 vaccine
RE
03:06pMODERNA : says COVID-19 shot maintains high efficacy through 6 months, sees even..
RE
02:07pMODERNA : U.S. administers nearly 349 mln doses of COVID-19 vaccines - CDC
RE
02:02pMODERNA : U.S. CDC Says Administered 348.97 Million Doses Of Covid-19 Vaccine As..
RE
12:16pMODERNA : says its COVID-19 shot maintains high efficacy through 6 months
RE
11:39aGLOBAL MARKETS LIVE : Robinhood, Bayer, MetLife, Uber, WPP...
11:25aModerna says vaccine is 93% effective six months later
RE
11:05aTHE LATEST : Moderna plans booster doses to help fight virus
AQ
More news
Financials (USD)
Sales 2021 19 117 M - -
Net income 2021 10 725 M - -
Net cash 2021 11 948 M - -
P/E ratio 2021 16,5x
Yield 2021 -
Capitalization 167 B 167 B -
EV / Sales 2021 8,12x
EV / Sales 2022 9,22x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 416,26 $
Average target price 187,80 $
Spread / Average Target -54,9%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.301.12%168 260
LONZA GROUP AG26.76%59 023
IQVIA HOLDINGS INC.39.45%47 876
CELLTRION, INC.-25.07%32 166
SEAGEN INC.-6.81%29 694
PHARMARON BEIJING CO., LTD.94.07%26 319